Clinical trials: Prostate Cancer, Castration Resistant
Prostate Cancer
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in…
- Trial name
- PROMET II (NCT02282644)
- Testing
- Bone marrow sampling
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer…
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
- Trial name
- NCT04381832
- Testing
- Etrumadenant, Zimberelimab, Quemliclustat
- Where
- 19 sites in United States, Canada
- Volunteers
- 173 people
- Sponsor
- Arcus Biosciences, Inc.
Prostate Cancer
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
- Trial name
- STAAR (NCT02737332)
- Testing
- Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
- Where
- 17 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer
GX301 is an experimental therapeutic vaccine directed against human telomerase, an enzyme playing an essential role in cancer cell proliferation.
- Trial name
- NCT02293707
- Testing
- GX301
- Where
- 24 sites in Italy, Spain
- Volunteers
- 99 people
- Sponsor
- Laboratoires Leurquin Mediolanum
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned.
- Trial name
- PREDICT (NCT06632977)
- Testing
- Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging
- Where
- 108 sites in United States
- Volunteers
- 474 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT05942001
- Testing
- HRS-5041, Docetaxel injection, Abiraterone acetate tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Radiologically Guided Biopsies of mCRPC
The purpose of this study is to better understand how cancer treatment may affect cancer cells. The research will involve genetic, molecular, cellular, and immunologic experiments using blood and tumor specimens.
- Trial name
- NCT02432001
- Testing
- Image-Guided Biopsies
- Where
- 5 sites in United States, Canada
- Volunteers
- 256 people
- Sponsor
- University of California, San Francisco
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Prostate Cancer
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
The purpose of this study is to determine the safety and optimal dosing of intravenous copper chloride and disulfiram in men with metastatic castrate-resistant prostate cancer (CRPC).
- Trial name
- NCT02963051
- Testing
- Copper, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel George, MD
Metastatic Castration-resistant Prostate Cancer
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed…
- Trial name
- NCT05457257
- Testing
- olaparib, enzalutamide, abiraterone acetate
- Where
- 35 sites in China
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.
- Trial name
- NCT01331083
- Testing
- PX-866
- Where
- 10 sites in Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Castration-resistant Prostate Cancer, Metastatic Cancer
Predictive Nomogram of CRPC
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the risk factors, then develop and validate the predictive Nomogram of…
- Trial name
- CRPC-PN (NCT03177551)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
D011471, D064129
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION
Observational prospective study investigating the plasmatic levels of miRNA according to AR-V7 mutational status in mCRPC patients receiving standard of care therapy.
- Conditions
- D011471, D064129, D035683, D009360
- Trial name
- PRIMERA (NCT04188275)
- Testing
- Periodic ARV7 and miRNA evaluation
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study.
- Trial name
- mCRPC (NCT01338012)
- Testing
- sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dendreon
Metastatic Castration-resistant Prostate Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC.
- Trial name
- NCT06909825
- Testing
- FPI-2265, Olaparib
- Where
- 4 sites in Australia
- Volunteers
- 85 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Castration-resistant Prostate Cancer, Metastasis
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination…
- Trial name
- PRO-CARBO (NCT03652493)
- Testing
- Carboplatin
- Where
- 4 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Francois Baclesse
Prostate Cancer
Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
- Trial name
- NCT00861614
- Testing
- Ipilimumab
- Where
- 158 sites in United States, Argentina and 25 more
- Volunteers
- 988 people
- Sponsor
- Bristol-Myers Squibb
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
- Trial name
- NCT05479578
- Testing
- Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rashmi Verma, MD
Prostate Cancer, Prostatic Neoplasms
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
This is a Phase Ib/IIa Study of Cabazitaxel plus Bavituximab in patients with castration-resistant prostate cancer (CRPC). The current study is designed to determine if the addition of bavituximab to cabazitaxel will improve…
- Trial name
- NCT01335204
- Testing
- Cabazitaxel plus bavituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medical University of South Carolina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.